Background: Dysfunctional Uterine Bleeding is defined as abnormal uterine bleeding in the absence of organic disease. Menorrhagia (menstrual blood loss >80 ml per cycle) affects 10 -33% ofwomen at some stage in their lives. Many Pharmacological treatment options are available for DUB. Norethisterone is the commonly used progesterone. Progesterone therapy for 21 days of the cycle results in a significant reduction in menstrual blood loss and can be used for both ovulatory as well as anovulatory. Ormeloxifene is a selective estrogen receptor modulator or SERM which is anti-estrogenic on endometrium and breast while estrogenic on bones, vagina, and cardiovascular systems.The present study was conducted to compare both in the treatment of DUB. Material and Methods: Sixty women presenting with DUB were randomly allocated to 2 equalgroups, Group-A, which received 60 mg ormeloxifene twice a week for 12 weeks followed by 60mg once a week for next 12 weeks and Group-Bwhich received 5 mg norethisterone twice daily for 21 days for 3 months. The primary outcomemeasures were reduction in menstrual blood loss which was measured by fall in PBAC (Pictorial Blood loss Assessment Chart) score, rise in hemoglobin level and reduction in endometrial thickness. Results: The reduction in mean PBAC score with ormeloxifene (294 to 64) was significantlymore than that seen with norethisterone (288 to 103) after 3 months of therapy (p<0.05). Theincrease in hemoglobin level and reduction in endometrial thickness were also found to besignificantly more with ormeloxifene than norethisterone (9.02 g% to 11.51 g% vs. 9.12 g% to 10.43 g%, p<0.05, and 7.4 mm to 5.1 mm vs. 6.9 mm to 5.7 mm, p<0.05, respectively). Conclusion: Ormeloxifene was found to be more effective than norethisterone in reducing blood loss and reducing endometrial thickness.